Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

When NICE recommends a treatment as an option for use during the managed access period, NHS England will make it available according to the conditions in the managed access agreement. This means that, if a patient has untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations and the healthcare professional responsible for their care thinks that amivantamab with carboplatin and pemetrexed is the right treatment, it should be available for use, in line with NICE's recommendations and the criteria in the managed access agreement.

Drugs with a draft recommendation for use in the Cancer Drugs Fund will be funded in line with the terms of their managed access agreement from the point of marketing authorisation, or from release of positive draft guidance, whichever is later. See chapter 2 of Appraisal and funding of cancer drugs from July 2016 (including the new Cancer Drugs Fund) – A new deal for patients, taxpayers and industry. The NHS England Cancer Drugs Fund list provides up-to-date information on all cancer treatments recommended by NICE since 2016. This includes whether they have received a marketing authorisation and been launched in the UK.

The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance when the drug or treatment, or other technology, is approved for use during the managed access period. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, for use during the managed access period, the NHS in Wales must usually provide funding and resources for it within 60 days of the first publication of the final draft guidance or agreement of a managed access agreement by the NHS in Wales, whichever is the later.